title: Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Percy
authors.forename: Sally E
authors.initials: SE
authors.lastname: Moore
authors.forename: Wendi
authors.initials: W
authors.lastname: Qian
authors.forename: Jude
authors.initials: J
authors.lastname: Dorman
authors.forename: Neil
authors.initials: N
authors.lastname: Rabin
authors.forename: Michael
authors.initials: M
authors.lastname: Watts
authors.forename: David C
authors.initials: DC
authors.lastname: Linch
authors.forename: Kwee L
authors.initials: KL
authors.lastname: Yong
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome